Verona Pharma Plc Overview
Get informed when a big investor buys or sells
+ Follow-63.64
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Verona Pharma Plc (VRNA) currently reports a P/E ratio of -63.64. That is below the Healthcare sector average of 70.94. Use the charts on this page to explore Verona Pharma Plc's P/E ratio history and peer comparisons.
Verona Pharma Plc's P/E ratio of -63.64 is lower than the Healthcare sector average of 70.94. That is roughly 189.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Verona Pharma Plc's market price to a fundamental measure such as earnings, sales, or book value. At -63.64, VRNA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -63.64, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 70.94. From there, open related valuation or income-statement pages for Verona Pharma Plc, and consider following VRNA for alerts when major investors trade the stock.
Verona Pharma Plc is classified in the Healthcare sector. On P/E ratio, it currently shows -63.64 versus a sector average near 70.94. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRNA with unrelated industries.
